创新药午后爆发，多重催化打开板块配置窗口，恒生创新药ETF（159316）等产品获资金关注

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a resurgence, with significant inflows into related ETFs indicating a rapid recovery in market sentiment [1][2] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.4%, while the CSI Innovative Drug Industry Index increased by 0.9% as of 14:40 [1] - Over the past five days, innovative drug-related ETFs, such as the Hang Seng Innovative Drug ETF (159316) and the E Fund Innovative Drug ETF (516080), have seen a net inflow exceeding 7 billion yuan, reflecting positive market dynamics [1] Group 2 - The acquisition of Metsera by Pfizer highlights the intensifying competition among multinational corporations for popular innovative drug pipelines, enhancing the overseas value and attractiveness of Chinese innovative drug companies [1] - The third-quarter net profit of the pharmaceutical sector increased by 7.7% year-on-year, with innovative drugs and other sub-sectors showing strong performance, providing a solid foundation for valuation recovery [1] - The first version of the commercial insurance innovative drug catalog is set to be released in early December, which is expected to expand payment channels and serve as a new engine for the growth of innovative drugs [1]